Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10138479
APP PUB NO 20150110773A1
SERIAL NO

14402824

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DANA-FARBER CANCER INSTITUTE, INC.; BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cantley, Lewis Cambridge, US 9 65
Kimmelman, Alec Weston, US 1 0
Lyssiotis, Costas A Jamaica Plain, US 3 25
Son, Jaekyoung Somerville, US 3 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 27, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 27, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00